The statement contains factual inaccuracies. The Biden administration did not remove safeguards for mifepristone; the FDA under Biden expanded access (including telehealth and mail-order) but maintained the drug's approval and safety monitoring. Additionally, describing mifepristone as 'dangerous' is misleading—major medical organizations consider it safe and effective, with serious complications being rare. The Fifth Circuit did rule to restrict access in 2023 (not 2026), but the claim that the Biden administration 'endangered lives by removing safeguards' is false.

The Biden administration did not remove safeguards for mifepristone; it maintained or expanded access to the drug. The claim that it endangered women and girls by removing safeguards is therefore false.

The Biden administration actually eased restrictions on mifepristone, expanding access rather than removing safety safeguards; there is no evidence that it endangered women’s health, making the claim false.

The statement contains subjective characterizations (mifepristone as 'dangerous', administration actions as 'endangering lives') rather than verifiable facts. Additionally, the date referenced (May 2, 2026) appears incorrect as